ERBB2 and cancer: Furthermore, patients with ER-negative, progesterone receptor (PR)-negative and HER2-negative tumours (triple-negative, or basal-like cancers) lack an established therapeutic target and can only be treated with conventional chemotherapy (Linn and Van ‘t Veer, 2009).